Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cardiovascular Systems (CSII), Intellia Therapeutics (NTLA) and IGM Biosciences (IGMS).
Cardiovascular Systems (CSII)
In a report issued on May 7, Danielle Antalffy from Leerink Partners maintained a Buy rating on Cardiovascular Systems, with a price target of $50.00. The company’s shares closed last Monday at $34.41.
According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 21.5% and a 64.5% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Tandem Diabetes Care, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardiovascular Systems with a $48.25 average price target, a 35.7% upside from current levels. In a report issued on May 7, Needham also maintained a Buy rating on the stock with a $50.00 price target.
See today’s analyst top recommended stocks >>
Intellia Therapeutics (NTLA)
Robert W. Baird analyst Brian Skorney assigned a Hold rating to Intellia Therapeutics on May 7 and set a price target of $60.00. The company’s shares closed last Monday at $61.03.
According to TipRanks.com, Skorney is a 3-star analyst with an average return of 4.0% and a 48.0% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $85.56 average price target, which is a 25.9% upside from current levels. In a report issued on May 6, Oppenheimer also maintained a Hold rating on the stock.
IGM Biosciences (IGMS)
In a report issued on May 7, Colleen M. Kusy from Robert W. Baird assigned a Buy rating to IGM Biosciences, with a price target of $90.00. The company’s shares closed last Monday at $65.66.
According to TipRanks.com, Kusy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.4% and a 18.2% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Apellis Pharmaceuticals, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IGM Biosciences with a $107.50 average price target, implying a 62.4% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $107.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.